aTyr Pharma plans to begin study-related activities in the fourth quarter of 2026 after reaching FDA alignment on a global Phase 3 efzofitimod trial, although further development will require additional capital.
Key Investor Takeaways
- aTyr Pharma (NASDAQ:ATYR) has reached alignment with the FDA on the protocol for a Phase 3 efzofitimod study in pulmonary sarcoidosis.
- The 54-week global trial is intended to enroll up to approximately 372 patients, comparing 5.0 mg/kg efzofitimod with placebo.
- The primary endpoint will measure change in forced vital capacity at week 48, with the KSQ-Lung score serving as the key secondary endpoint.
- The Phase 3 study design follows a subgroup analysis from EFZO-FIT showing benefits in lung function and patient-reported outcomes for patients with restrictive lung disease.
- Funding is a material consideration: aTyr said future Phase 3 development will require additional capital from financing, grants, partnerships or licensing arrangements.
Why ATYR Stock Is in Focus
aTyr Pharma has reached agreement with the FDA on the protocol for its planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
The global, randomized, double-blind and placebo-controlled trial will include two parallel cohorts. Patients will be randomized equally to receive either 5.0 mg/kg efzofitimod or placebo intravenously once every three weeks, for a total of 17 doses over the 54-week study.
aTyr intends to enroll up to approximately 372 patients receiving a stable dose of no more than 5.0 mg per day of oral corticosteroids and/or a background immunosuppressant. Existing background treatment will remain stable during the study.
The primary endpoint is change from baseline in forced vital capacity, or FVC, at week 48. The key secondary endpoint will assess change in the King’s Sarcoidosis Questionnaire Lung score at the same point.
aTyr expects to initiate study-related activities during the fourth quarter of 2026 while focusing on regulatory submissions in the U.S. and Europe.
Why This Matters for Investors
FDA alignment provides a defined regulatory and clinical framework for the next Phase 3 evaluation of efzofitimod. For investors, attention now shifts from protocol discussions toward the company’s ability to initiate and execute the study.
The trial design is supported by a subgroup analysis from the Phase 3 EFZO-FIT study. According to aTyr, patients with pulmonary sarcoidosis and restrictive lung disease receiving 5.0 mg/kg efzofitimod showed a clinically meaningful benefit in FVC and improvements across several patient-reported outcomes, including the KSQ-Lung score, compared with placebo.
However, the company has also identified a significant financing requirement. aTyr said future development of efzofitimod in the planned Phase 3 trial will require additional capital through equity or debt offerings, grants, collaborations, strategic partnerships and/or licensing arrangements.
That makes funding alongside clinical execution an important part of the investment narrative as the program advances toward another late-stage study.
What to Watch Next
The immediate milestones are regulatory submissions in the U.S. and Europe and the start of Phase 3 study-related activities in the fourth quarter of 2026.
Investors will also be watching for details on trial initiation and enrollment, as well as how aTyr secures the additional capital required to fund efzofitimod’s continued development.
Efzofitimod is separately being evaluated in the Phase 2 EFZO-CONNECT study in patients with systemic sclerosis-related interstitial lung disease, providing another clinical program to monitor.